4:54 PM
 | 
Dec 08, 2016
 |  BC Extra  |  Clinical News

Horizon dips on Phase III Friedreich's ataxia miss

Horizon Pharma plc (NASDAQ:HZNP) dropped $4.36 (22%) to $15.03 on Thursday after it said Actimmune interferon (IFN) gamma-1b missed the primary endpoint in the Phase III STEADFAST...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >